ARKEMA FADES AWAY (BUY; +39% UPSIDE)

03/09/24 -" Portfolio rotation has been a key profitability driver and a crucial aspect of Arkema’s (Buy; France) equity narrative. Its 2028 targets appear to be more of the same, and achieving them becomes ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

03/09/24

Download

You may also be interested by these reports :

15/07/25

K+S

Positive momentum fading, time to collect profit

15/07/25

Solvay

Solvay has confirmed our cautious view by cutting the FY EBITDA guidance to €880-930m, down from the previous target of the lower half of the ...

15/07/25

REC Silicon

We are increasingly optimistic about working capital management in the coming years, anticipating higher inflows. However, we have reduced the ...

14/07/25

Givaudan

Givaudan remains a preferred defensive option ahead of the 1H25E results

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue